Alpha 1 Lung Disease Market
完整報告名稱與涵蓋範圍
Alpha 1 Lung Disease Market Size, Share & Trends Analysis Report By Disease Type (Alpha-1 Antitrypsin Deficiency, Chronic Obstructive Pulmonary Disease (COPD), Pulmonary Fibrosis, Bronchiectasis, Others), By Treatment Type (Augmentation Therapy, Bronchodilators, Corticosteroids, Oxygen Therapy, Lung Transplantation, Others), By Route of Administration, By Distribution Channel, By End User, By Region, And By Segment Forecasts, 2023-2031.
報告摘要
The worldwide Alpha 1 Lung Disease Market stood at USD 4.13 Billion in 2022, and is projected to reach USD 19.93 Billion by 2031, recording a CAGR of 19.33% from 2023 through 2031.
At its core, Alpha 1 Lung Disease pertains to a genetic disorder in which the body does not make enough of a protein known as alpha-1 antitrypsin. Stakeholders across the healthcare landscape are risingly turning to these solutions to meet contemporary demands.
Growth is driven by a convergence of factors: rising awareness among end users, continuous product innovation, and the rising emphasis on efficiency and sustainability within the healthcare sector.
The market landscape is structured across several key segments—spanning type, application, distribution channel, and region—each contributing uniquely to overall market expansion.
Geographically, North America maintains a leading position owing to advanced infrastructure, high R&D expenditure, and a well-established regulatory environment. Meanwhile, Asia-Pacific is emerging as the fastest-growing region, driven by rapid industrialization and expanding end-user bases.
The competitive arena features a mix of established conglomerates and agile innovators, each vying for market position through strategic acquisitions, product launches, and capacity expansion.
This comprehensive research study delivers granular insights into market sizing, trend analysis, competitive benchmarking, and forward-looking projections to support strategic decision-making for industry participants and investors.
授權報價
| Single User PDF | $4,500 USD |
| Global Site License PDF | $9,500 USD |
目錄 Table of Contents
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Alpha 1 Lung Disease Market Snapshot
Chapter 4. Global Alpha 1 Lung Disease Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis – Porter's Five Forces Analysis
4.7. Competitive Landscape & Market Share Analysis
4.8. Impact of Covid-19 Analysis
Chapter 5. Market Segmentation 1: By Disease Type Estimates & Trend Analysis
5.1. By Disease Type, & Market Share, 2019 & 2031
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2023 to 2031 for the following By Disease Type:
5.2.1. Alpha-1 Antitrypsin Deficiency
5.2.2. Chronic Obstructive Pulmonary Disease (COPD)
5.2.3. Pulmonary Fibrosis
5.2.4. Bronchiectasis
5.2.5. Others
Chapter 6. Market Segmentation 2: By Treatment Type Estimates & Trend Analysis
6.1. By Treatment Type & Market Share, 2019 & 2031
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2023 to 2031 for the following By Treatment Type:
6.2.1. Augmentation Therapy
6.2.2. Bronchodilators
6.2.3. Corticosteroids
6.2.4. Oxygen Therapy
6.2.5. Lung Transplantation
6.2.6. Others
Chapter 7. Market Segmentation 3: By Route of Administration Estimates & Trend Analysis
7.1. By Route of Administration & Market Share, 2019 & 2031
7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2023 to 2031 for the following By Route of Administration:
7.2.1. Inhalation
7.2.2. Injectable
7.2.3. Oral
Chapter 8. Market Segmentation 4: By Distribution Channel Estimates & Trend Analysis
8.1. By Distribution Channel & Market Share, 2019 & 2031
8.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2023 to 2031 for the following By Distribution Channel:
8.2.1. Hospital Pharmacies
8.2.2. Retail Pharmacies
8.2.3. Online Pharmacies
Chapter 9. Market Segmentation 5: By End-Users Estimates & Trend Analysis
9.1. By End-Users & Market Share, 2019 & 2031
9.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2023 to 2031 for the following By End-Users:
9.2.1. Hospitals
9.2.2. Homecare
9.2.3. Specialty Clinics
9.2.4. Others
Chapter 10. Alpha 1 Lung Disease Market Segmentation 6: Regional Estimates & Trend Analysis
10.1. North America
10.1.1. North America Alpha 1 Lung Disease Market revenue (US$ Million) estimates and forecasts By Disease Type, 2023-2031
10.1.2. North America Alpha 1 Lung Disease Market revenue (US$ Million) estimates and forecasts By Treatment Type, 2023-2031
10.1.3. North America Alpha 1 Lung Disease Market revenue (US$ Million) estimates and forecasts By Route of Administration, 2023-2031
10.1.4. North America Alpha 1 Lung Disease Market revenue (US$ Million) estimates and forecasts By Distribution Channel, 2023-2031
10.1.5. North America Alpha 1 Lung Disease Market revenue (US$ Million) estimates and forecasts By End-Users, 2023-2031
10.1.6. North America Alpha 1 Lung Disease Market revenue (US$ Million) estimates and forecasts by country, 2023-2031
10.2. Europe
10.2.1. Europe Alpha 1 Lung Disease Market revenue (US$ Million) By Disease Type, 2023-2031
10.2.2. Europe Alpha 1 Lung Disease Market revenue (US$ Million) By Treatment Type, 2023-2031
10.2.3. Europe Alpha 1 Lung Disease Market revenue (US$ Million) By Route of Administration, 2023-2031
10.2.4. Europe Alpha 1 Lung Disease Market revenue (US$ Million) By Distribution Channel, 2023-2031
10.2.5. Europe Alpha 1 Lung Disease Market revenue (US$ Million) By End-Users, 2023-2031
10.2.6. Europe Alpha 1 Lung Disease Market revenue (US$ Million) by country, 2023-2031
10.3. Asia Pacific
10.3.1. Asia Pacific Alpha 1 Lung Disease Market revenue (US$ Million) By Disease Type, 2023-2031
10.3.2. Asia Pacific Alpha 1 Lung Disease Market revenue (US$ Million) By Treatment Type, 2023-2031
10.3.3. Asia Pacific Alpha 1 Lung Disease Market revenue (US$ Million) By Route of Administration, 2023-2031
10.3.4. Asia Pacific Alpha 1 Lung Disease Market revenue (US$ Million) By Distribution Channel, 2023-2031
10.3.5. Asia Pacific Alpha 1 Lung Disease Market revenue (US$ Million) By End-Users, 2023-2031
10.3.6. Asia Pacific Alpha 1 Lung Disease Market revenue (US$ Million) by country, 2023-2031
10.4. Latin America
10.4.1. Latin America Alpha 1 Lung Disease Market revenue (US$ Million) By Disease Type, (US$ Million) 2023-2031
10.4.2. Latin America Alpha 1 Lung Disease Market revenue (US$ Million) By Treatment Type, (US$ Million) 2023-2031
10.4.3. Latin America Alpha 1 Lung Disease Market revenue (US$ Million) By Route of Administration, (US$ Million) 2023-2031
10.4.4. Latin America Alpha 1 Lung Disease Market revenue (US$ Million) By Distribution Channel, (US$ Million) 2023-2031
10.4.5. Latin America Alpha 1 Lung Disease Market revenue (US$ Million) By End-Users, (US$ Million) 2023-2031
10.4.6. Latin America Alpha 1 Lung Disease Market revenue (US$ Million) by country, 2023-2031
10.5. Middle East & Africa
10.5.1. Middle East & Africa Alpha 1 Lung Disease Market revenue (US$ Million) By Disease Type, (US$ Million) 2023-2031
10.5.2. Middle East & Africa Alpha 1 Lung Disease Market revenue (US$ Million) By Treatment Type, (US$ Million) 2023-2031
10.5.3. Middle East & Africa Alpha 1 Lung Disease Market revenue (US$ Million) By Route of Administration, (US$ Million) 2023-2031
10.5.4. Middle East & Africa Alpha 1 Lung Disease Market revenue (US$ Million) By Distribution Channel, (US$ Million) 2023-2031
10.5.5. Middle East & Africa Alpha 1 Lung Disease Market revenue (US$ Million) By End-Users, (US$ Million) 2023-2031
10.5.6. Middle East & Africa Alpha 1 Lung Disease Market revenue (US$ Million) by country, 2023-2031
Chapter 11. Competitive Landscape
11.1. Major Mergers and Acquisitions/Strategic Alliances
11.2. Company Profiles
11.2.1. AstraZeneca,
11.2.2. Boehringer Ingelheim,
11.2.3. Roche ,
11.2.4. Novartis,
11.2.5. Pfizer,
11.2.6. Merck,
11.2.7. Bristol-Myers Squibb,
11.2.8. Takeda Pharmaceutical,
11.2.9. CSL Behring,
11.2.10. Vertex Pharmaceuticals,
11.2.11. Amgen,
11.2.12. Sanofi,
11.2.13. GlaxoSmithKline,
11.2.14. Gilead Sciences ,
11.2.15. Eli Lilly,
11.2.16. AbbVie,
11.2.17. Johnson & Johnson,
11.2.18. Teva Pharmaceutical,
11.2.19. Audentes Therapeutics,
11.2.20. Regeneron Pharmaceuticals
11.2.21. LFB Biomedicaments
11.2.22. Grifols
11.2.23. Kamada Ltd
11.2.24. Others
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 InsightAce Analytic 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們